BCG vaccination provides protection against IAV but not SARS-CoV-2

BCG 疫苗可预防 IAV,但不能预防 SARS-CoV-2

阅读:9
作者:Eva Kaufmann, Nargis Khan, Kim A Tran, Antigona Ulndreaj, Erwan Pernet, Ghislaine Fontes, Andréanne Lupien, Patrice Desmeules, Fiona McIntosh, Amina Abow, Simone J C F M Moorlag, Priya Debisarun, Karen Mossman, Arinjay Banerjee, Danielle Karo-Atar, Mina Sadeghi, Samira Mubareka, Donald C Vinh, Irah

Abstract

Since the vast majority of species solely rely on innate immunity for host defense, it stands to reason that a critical evolutionary trait like immunological memory evolved in this primitive branch of our immune system. There is ample evidence that vaccines such as bacillus Calmette-Guérin (BCG) induce protective innate immune memory responses (trained immunity) against heterologous pathogens. Here we show that while BCG vaccination significantly reduces morbidity and mortality against influenza A virus (IAV), it fails to provide protection against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In contrast to IAV, SARS-CoV-2 infection leads to unique pulmonary vasculature damage facilitating viral dissemination to other organs, including the bone marrow (BM), a central site for BCG-mediated trained immunity. Finally, monocytes from BCG-vaccinated individuals mount an efficient cytokine response to IAV infection, while this response is minimal following SARS-CoV-2. Collectively, our data suggest that the protective capacity of BCG vaccination is contingent on viral pathogenesis and tissue tropism.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。